pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
ISATUXIMAB
Phase 2 · small molecule · Isatuximab in type I cryoglobulinaemia: A prospective pilot study
ISATUXIMAB for Isatuximab in type I cryoglobulinaemia: A prospective pilot study is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP210369
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Isatuximab in type I cryoglobulinaemia: A prospective pilot study
- Status
- active
- Trials
- 1